Zegalogue
Zegalogue Mechanism of Action Buprenorphine – the active ingredient in Zegalogue is a partial agonist at the μ‑opioid receptor (MOR). Provides analgesia and a protective effect against opioid withdrawal. Ceiling…
Zebeta
Zebeta Zebeta is a next‑generation β₂‑adrenergic receptor antagonist indicated primarily for the treatment of hypertension, angina pectoris, supraventricular tachycardia, migraine prophylaxis, and anxiety‑related tachycardia. Mechanism of Action Selective antagonism of…
Zarxio
Zarxio Mechanism of Action Zarxio functions as a selective JAK2/TYK2 inhibitor, binding to the ATP‑binding pocket of JAK2 and blocking phosphorylation of downstream STAT signaling pathways. Inhibition reduces transcription of…
Zanubrutinib
Zanubrutinib Zanubrutinib (Brukinsa™) is a highly selective, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor used primarily in relapsed/refractory B‑cell malignancies and certain chronic lymphocytic leukemia (CLL) cases. --- Mechanism of Action…
Zantac
Zantac Zantac (generic name ranitidine) is a histamine‑H₂ receptor antagonist that reduces gastric acid secretion. Although withdrawn from many markets due to contamination concerns, it remains available in certain countries;…
Zanaflex
Zanaflex Zanaflex (tizanidine) is a short‑acting prescription medication used primarily to relieve muscle spasticity. It belongs to the class of α₂‑adrenergic agonists and offers a quick onset of action with…
Zaleplon
Zaleplon Zaleplon (brand name Sonata) is a short‑acting hypnotic of the benzodiazepine receptor agonist class used for the acute treatment of insomnia. Mechanism of Action Zaleplon acts as a positive…
Yuvafem
Yuvafem Yuvafem is a low‑dose oral estrogen‑phytoestrogen combination used primarily for the relief of menopausal symptoms and the prevention of osteoporotic fractures in estrogen‑deficient women. Mechanism of Action Low‑dose 17‑β‑estradiol…
Yutrepia
Yutrepia Yutrepia is a recently approved oral small‑molecule inhibitor that selectively targets Janus kinase pathways. Its design balances potency against JAK1/JAK3 with a favorable safety profile, making it a compelling…
Yusimry
Yusimry Yusimry is a recently developed oral therapeutic agent currently in late‑phase clinical development. It is being investigated for the treatment of moderate‑to‑severe chronic inflammatory disorders such as ulcerative colitis…